Ikena Oncology, Inc. (IKNA) News

Ikena Oncology, Inc. (IKNA): $4.50

0.27 (+6.38%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IKNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Filter IKNA News Items

IKNA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IKNA News Highlights

  • For IKNA, its 30 day story count is now at 2.
  • Over the past 8 days, the trend for IKNA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about IKNA are DRUG.

Latest IKNA News From Around the Web

Below are the latest news stories about Ikena Oncology Inc that investors may wish to consider to help them evaluate IKNA as an investment opportunity.

Top 10 Stock Picks of Samuel Isaly’s OrbiMed Advisors

In this article, we discuss the top 10 stock picks of Samuel Isaly’s OrbiMed Advisors. If you want to skip our detailed analysis of Isaly’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Samuel Isaly’s OrbiMed Advisors. Samuel Isaly graduated from Princeton University with an A.B. in Economics […]

Yahoo | February 3, 2022

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors. Dr. Wooster brings more than 30 years of experience in oncology drug discovery and development and dissecting the genetics of cancer and will provide invaluable insight to Ikena as the Company progresses several programs to benefit pat

Yahoo | January 26, 2022

Ikena Oncology (NASDAQ:IKNA) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Ikena Oncology (NASDAQ:IKNA) in a research report sent to investors on Thursday morning, Analyst Ratings Network reports. The brokerage issued a buy rating and a $25.00 target price on the stock. Separately, Zacks Investment Research downgraded shares of Ikena Oncology from a buy rating to a hold rating []

Transcript Daily | December 24, 2021

Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ...

New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc.

Yahoo | December 24, 2021

Analysts Offer Insights on Healthcare Companies: HTG Molecular Diagnostics (HTGM), Sol-Gel Technologies (SLGL) and Ikena Oncology (IKNA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on HTG Molecular Diagnostics (HTGM – Research Report), Sol-Gel Technologies (SLGL – Research Report) and Ikena Oncology (IKNA – Research Report) with bullish sentiments. HTG Molecular Diagnostics (HTGM) H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics today and set a price target of $9.00. The company's shares closed last Wednesday at $3.70, close to its 52-week low of $3.20. According to TipRanks.

Catie Powers on TipRanks | December 23, 2021

Here's Why We're Not Too Worried About Ikena Oncology's (NASDAQ:IKNA) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 23, 2021

Ikena Oncology, Inc. (NASDAQ:IKNA) Director Jean Francois Formela Sells 8,330 Shares

Ikena Oncology, Inc. (NASDAQ:IKNA) Director Jean Francois Formela sold 8,330 shares of the firms stock in a transaction on Monday, December 13th. The shares were sold at an average price of $14.64, for a total transaction of $121,951.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through []

Transcript Daily | December 17, 2021

Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies

Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited partner capital commitments. The new fund, Omega Fund VII, L.P. ("Fund VII"), was oversubscribed, exceeding the firm's targeted raise of $500 million, and included strong support from both new and existing limited partners. With Fund VII, the firm will continue to execute on its strategy

Yahoo | December 17, 2021

Ikena Oncology (NASDAQ:IKNA) Trading Down 7.6%

Ikena Oncology, Inc. (NASDAQ:IKNA) traded down 7.6% during mid-day trading on Friday . The stock traded as low as $14.42 and last traded at $14.42. 2,532 shares were traded during mid-day trading, a decline of 98% from the average session volume of 146,454 shares. The stock had previously closed at $15.61. Several analysts have recently […]

Transcript Daily | December 10, 2021

Ikena Oncology (NASDAQ:IKNA) Trading 11.4% Higher

Ikena Oncology, Inc. (NASDAQ:IKNA) shares traded up 11.4% on Tuesday . The stock traded as high as $14.34 and last traded at $13.99. 4,337 shares were traded during trading, a decline of 97% from the average session volume of 146,011 shares. The stock had previously closed at $12.56. Several equities analysts have recently weighed in []

Transcript Daily | December 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7157 seconds.